Economic evaluation guidelines in Latin America: a current snapshot

scientific article published on October 1, 2010

Economic evaluation guidelines in Latin America: a current snapshot is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1586/ERP.10.56
P953full work available at URLhttp://www.future-drugs.com/doi/abs/10.1586/erp.10.56
http://www.tandfonline.com/doi/pdf/10.1586/erp.10.56
P698PubMed publication ID20950069

P50authorAndrés Pichon RiviereQ86047017
P2093author name stringFederico Augustovski
Osvaldo Ulises Garay
Adolfo Rubinstein
Joaquín E. Caporale
P2860cites workCost and cost-effectiveness guidelines: which ones to use?Q34174634
Health economic guidelines--similarities, differences and some implicationsQ34436165
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdleQ35925125
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.Q36948710
Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United KingdomQ50129944
The development of health technology assessment in Brazil.Q53100782
Health technology assessment in Mexico.Q53101300
Where are the economic guidelines coming from?Q73392116
Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluationQ81451309
Key principles for the improved conduct of health technology assessments for resource allocation decisionsQ81581696
Using economic evidence in reimbursement decisions for health technologies: experience of 4 countriesQ84642969
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)525-537
P577publication date2010-10-01
P1433published inExpert Review of Pharmacoeconomics & Outcomes ResearchQ15734522
P1476titleEconomic evaluation guidelines in Latin America: a current snapshot
P478volume10

Reverse relations

cites work (P2860)
Q38573098Cost effectiveness evaluation of a rotavirus vaccination program in Argentina
Q38845478Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
Q36089475Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs
Q36266671Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Q41728685IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.
Q52812131Measuring the Benefits of Healthcare: DALYs and QALYs - Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions.
Q51111203Medical devices: from licensing to coverage. highlights from Argentina, Brazil, Colombia and Mexico.
Q29353660Oxytocin in Uniject Disposable Auto-Disable Injection System versus Standard Use for the Prevention of Postpartum Hemorrhage in Latin America and the Caribbean: A Cost-Effectiveness Analysis
Q53141521Universal coverage with rising healthcare costs; health outcomes research value in decision-making in Latin America.
Q92054533[Health impact assessment of the Program Healthy Centers in the Autonomous City of Buenos Aires, ArgentinaAvaliação do impacto na saúde do Programa Estações Saudáveis na Cidade Autônoma de Buenos Aires, Argentina]

Search more.